Bibliografía del artículo
1. Cassone VM, Natesan AK. Time and time again: the phylogeny of melatonin as a transducer of biological time. J Biol Rhythms 1997; 12:489-497.
2. Brzezinski A. Melatonin in humans. N Eng J Med 1997; 336:186-195.
3. Lerner AB, Case JD, Takahashi Y, Lee TH, Mori W. Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Am Chem Soc 1958; 80:2587.
4. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991; 12:151-180.
5. Kvetnoy I. Extrapineal melatonin in pathology: new perspectives for diagnosis, prognosis and treatment of illness. Neuro Endocrinol Lett 2002; 23:92-96.
6. Cardinali DP. Melatonin. A mammalian pineal hormone. Endocr Rev 1981; 2:327-346.
7. Markey SP, Higa S, Shih M, Danforth DN, Tamarkin L. The correlation between human plasma melatonin levels and urinary 6-hydroxymelatonin excretion. Clin Chim Acta 1985; 150:221-225.
8. Tan DX, Manchester LC, Reiter RJ y col. A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation. Biochem Biophys Res Commun 1998; 253:614-620.
9. Reiter RJ. The melatonin rhythm: both a clock and a calendar. Experientia 1993; 49:654-664.
10. Pangerl B, Pangerl A, Reiter RJ.Circadian variations of adrenergic receptors in the mammalian pineal gland: a review. J Neural Transm Gen Sect 1990; 81:17-29.
11. Rubio A, Guerrero JM, Reiter RJ, Osuna C. Involvement of alpha- and beta-adrenergic receptors in the regulation of rat pineal N-acetyltransferase activity during development. Endocrinology 1993; 132:393-398.
12. Cardinali DP, Lynch HJ, Wurtman RJ. Binding of melatonin to human and rat plasma proteins. Endocrinology 1972; 91:1213-1218.
13. Reiter RJ. The pineal and its hormones in the control of reproduction in mammals. Endocr Rev 1980; 1:109-131.
14. Guerrero JM, Reiter RJ. Melatonin-immune system relationship. Curr Top Med Chem 2002; 2:167-179.
15. Reiter RJ, Tan DX. Melatonin: a novel protective agent against oxidative injury of the ischemic/reperfused heart. Cardiovasc Res 2003; 58:10-19.
16. Carrillo Vico A, García Maurino S, Calvo JR, Guerrero JM. Melatonin counteracts the inhibitory effect of PGE2 on IL-2 production in human lymphocytes via its mt1 membrane receptor. FASEB J 2003; 17:755-757.
17. Macchi MM, Bruce JN. Human pineal physiology and functional significance of melatonin. Front Neuroendocrinol 2004; 25:177-195.
18. Maestroni GJ. The immunoneuroendocrine role of melatonin. J Pineal Res 1993; 14:1-10.
19. Carrillo Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine 2005; 27:189-200.
20. Cuzzocrea S, Reiter RJ. Pharmacological actions of melatonin in shock, inflammation and ischemia/reperfusion injury. Eur J Pharmacol 2001; 426:1-10.
21. De Micheli A, Aranda A, Chávez E. Sustratos celulares del síndrome de infarto miocárdico agudo. Arch Inst Cardiol Mex 1995; 65:79-88.
22. Jennings RB, Murry CE, Steenberg C Jr, Reimer KA. Development of cell injury in sustained acute ischemia. Circulation 1990; 82(3 Suppl):II2-12.
23. Sommers HM, Jennings RB. Experimental acute myocardial infarction: histologic and histochemical studies of early myocardial infarcts induced by temporary or permanent occlusion of a coronary artery. Lab Invest 1964; 13:1491-502.
24. Cain BS, Meldrum D, Meng X, Shames B, Banerjee A, Harken A. Calcium preconditioning in human myocardium. Ann Thorac Surg 1998; 65:1065-70.
25. Téllez F, Carvajal K, García C, Vásquez C, Chávez E, Moreno Sánchez R. Bases bioquímicas y celulares del daño por isquemia y reperfusión en el miocardio. Arch Inst Cardiol Mex 1996; 66:162-81.
26. Flitter WD. Free radicals and myocardial reperfusion injury. Br Med Bull 1993; 49:545-55.
27. Lucas DT, Sweda LI. Cardiac reperfusión injury: aging, lipid peroxidation, and mithocondrial dysfunction. Proc Natl Acad SCI USA 1998; 95:510-4.
28. Basu S, Nozari A, Liu XL, Rubertson S, Wiklund L. Development of a novel biomarker of free radical damage in reperfusion injury after cardiac arrest. FEBS Lett Mar 17; 470:1-6.
29. Férez Santander SM, Márquez MF, Peña Duque MA, Ocaranza Sánchez R, De la Peña Almaguer E, Eid Lidt G. Daño miocárdico por reperfusión. Rev Esp Cardiol 2003; 57(Supl 1):9-21.
30. Vilar Rojas C, Guzmán Grenfell AM, Hicks JJ. Participation of oxygen-free radicals in the oxido-reduction of proteins. Arch Med Res 1996; 27:1-6.
31. Ambrosio G, Tritto T. Reperfusión injury: experimental evidence and clinical implications. Am Heart J 1999; 138(2Pt2):S69-75.
32. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxinitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87:1620-4.
33. De Scheerder IK, VandeKraay AMM, Lamers JMJ, Koster JF, De Jong JF, Serruys PW. Myocardial malondialdehyde and uric acid release after short-lasting coronary occlusions during coronary angioplasty: potential mechanisms for free radical generation. Am J Cardiol 1991; 68:392-5.
34. Brugger P, Marktl W, Herold M. Impaired nocturnal secretion of melatonin in coronary heart disease. Lancet 1995; 345:1408.
35. Sakotnik A, Liebmann P, Stoschitzki K y col. Decreased melatonin synthesis in patients with coronary artery disease. Eur Heart J 1999; 20:1314-1317.
36. Girotti L, Lago M, Ianovsky O y col. Low urinary 6-sulfatoxymelatonin levels in patients with severe congestive heart failure. Endocrine 2003; 22:245-8.
37. Altun A, Yaprak M, Aktoz M, Vardar A, Betul UA, Olzbay G. Impaired nocturnal synthesis of melatonin in patients with cardiac syndrome X. Neurosci Lett 2002; 327:143-145.
38. García González MJ, Abreu González P, Domínguez Rodríguez A, Marrero Rodríguez F, Sánchez Sánchez JJ. Síntesis de melatonina en pacientes con infarto agudo de miocardio. Rev Esp Cardiol 2002; 55(Supl 2):69.
39. Domínguez Rodríguez A, Abreu González P, García M, Sánchez J, Marrero F, Armas Trujillo D. Decreased nocturnal melatonin levels during acute myocardial infarction. J Pineal Res 2002; 33:248-252.
40. Tan DX, Manchester LC, Burkhardt S y col. N1-acetyl-N2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant. FASEB J 2001; 15:2294-2296.
41. Reiter RJ, Tan DX, Manchester LC, Qi W. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: a review of the evidence. Cell Biochem Biophys 2001; 34:237-256.
42. Ross R. Atherosclerosis-an inflammatory disease. N Eng J Med 1999; 340:115-126.
43. Domínguez Rodríguez A, Abreu González P, García González MJ, De la Rosa A, Vargas M, Marrero F. Ritmo luz/oscuridad de las citocinas proinflamatorias en el infarto agudo de miocardio. Rev Esp Cardiol 2003; 56:555-560.
44. Domínguez Rodríguez A, Abreu González P, García González MJ y col. Light/dark patterns of interleukin-6 in relation to the pineal hormone melatonin in patients with acute myocardial infarction. Cytokine 2004; 26:89-93.
45. Ekmekcioglu C. Melatonin receptors in humans: biological role and clinical relevance. Biomed Pharmacother 2006; 60:97-108.
46. Domínguez Rodríguez A, Abreu González P, García González M, Ferrer Hita J, Vargas M, Reiter RJ. Elevated levels of oxidized low-density lipoprotein and impaired nocturnal syntesis of melatonin in patients with myocardial infarction. Atherosclerosis 2005; 180:101-105.
47. Domínguez Rodríguez A, García González MJ, Abreu González P, Ferrer J, Kaski JC. Relation of nocturnal melatonin levels to C-reactive protein concentration in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2006; 97:10-12.
48. Domínguez Rodríguez A, Abreu González P, García González M, Reiter RJ. Prognostic value of nocturnal melatonin levels as a novel marker in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2006; 97:1162-4.
49. Domínguez Rodríguez A, Abreu González P, García González MJ, Kaski JC, Reiter RJ. The melatonin adjunct in the acute myocardial infarction treated with primary angioplasty: study design and rationale (MARIA TRIAL). Atherosclerosis 2006; 7(Suppl. 3):122.